Search

ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.

Benzathine penicillin G (BPG) has been in use since the 1950s for treatment of skin infections, bacterial pharyngitis, syphilis and prevention of recurrent episodes of acute rheumatic fever (ARF)

Reach works to promote the health of vulnerable populations by providing technical support to local, regional and global efforts to prevent and control rheumatic fever and rheumatic heart disease (RF/RHD).

This project aims to empower local clinicians with skills and knowledge of using handheld echocardiography (HAND) that will allow for mobile service provision into remote Indigenous communities.

In this study we will use new methods to comprehensively test immune responses in blood samples from people with ARF (diagnosed using the Jones Criteria) and healthy volunteers at Royal Darwin and from Auckland Hospital, New Zealand, to find any unique signature that reliably identifies ARF.

The END RHD CRE will undertake a number of projects across several disciplines of research including epidemiology, biomedical sciences; implementation and translation; and understanding the RHD community with a special focus on documenting the experiences of those living with the disease.

This work will be undertaken in collaboration with The Kids Research Institute Australia and Australian based research teams to better understand how Penicillin works in Māori and Pacific children/teens who receive monthly BPG injections.

Goal: Characterize the pattern of contemporary and endemic ARF and develop a biological signature to improve sensitivity and specificity of ARF diagnosis.

The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.

The key objective of this study is to collect data about patient and clinician preferences about reformulations.